Update
$Day One Biopharmaceuticals(DAWN.US$ Day One Announces FDA Acceptance Of NDA And Priority Review For Tovorafenib In Relapsed Or Progressive Pediatric Low-Grade Glioma
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
